Get the Stockscreener App
79.42
1.74%
-1.41
Overview
News
Price History
Option Chain
Financials
Why CVS Down?
Discussions
Forecast
Stock Split
Dividend History
Cvs Health Corp stock is traded at $79.42, with a volume of 6.32M.
It is down -1.74% in the last 24 hours and down -1.05% over the past month.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
See More
Previous Close:
$80.83
Open:
$81
24h Volume:
6.32M
Relative Volume:
0.85
Market Cap:
$100.82B
Revenue:
$393.94B
Net Income/Loss:
$428.00M
P/E Ratio:
207.58
EPS:
0.3826
Net Cash Flow:
$6.29B
1W Performance:
+5.01%
1M Performance:
-1.05%
6M Performance:
+19.70%
1Y Performance:
+60.19%
1-Day Range:
$78.67
$81.08
1-Week Range:
$75.00
$81.08
52-Week Range:
$43.56
$85.15
Cvs Health Corp Stock (CVS) Company Profile
Name
Cvs Health Corp
Sector
Industry
Phone
(401) 765-1500
Address
ONE CVS DR., WOONSOCKET
Compare CVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
79.42 | 102.61B | 393.94B | 428.00M | 6.29B | 0.3826 |
|
UNH
Unitedhealth Group Inc
|
341.84 | 305.02B | 435.16B | 18.37B | 17.37B | 19.16 |
|
ELV
Elevance Health Inc
|
359.07 | 80.05B | 194.82B | 5.53B | 3.77B | 24.45 |
|
CI
Cigna Group
|
274.70 | 72.73B | 268.22B | 6.55B | 7.44B | 22.67 |
|
HUM
Humana Inc
|
268.45 | 32.05B | 123.11B | 1.58B | 2.44B | 13.03 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Goldman | Buy |
| Aug-18-25 | Upgrade | UBS | Neutral → Buy |
| Aug-14-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-13-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-12-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-30-25 | Upgrade | Edward Jones | Hold → Buy |
| Dec-03-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-18-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-04-24 | Upgrade | TD Cowen | Hold → Buy |
| May-30-24 | Initiated | Robert W. Baird | Neutral |
| May-07-24 | Downgrade | TD Cowen | Buy → Hold |
| May-02-24 | Downgrade | UBS | Buy → Neutral |
| May-01-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-01-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Dec-22-23 | Initiated | HSBC Securities | Buy |
| Sep-19-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-12-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-18-23 | Downgrade | Edward Jones | Buy → Hold |
| May-26-23 | Initiated | Piper Sandler | Overweight |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Resumed | Morgan Stanley | Overweight |
| Jun-17-22 | Initiated | Loop Capital | Buy |
| May-27-22 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-29-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-14-21 | Initiated | Goldman | Buy |
| Dec-01-21 | Initiated | Seaport Research Partners | Buy |
| May-19-21 | Initiated | Wells Fargo | Equal Weight |
| Mar-17-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-08-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-17-20 | Initiated | Piper Sandler | Overweight |
| Jul-01-20 | Initiated | SVB Leerink | Mkt Perform |
| May-14-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-27-19 | Resumed | RBC Capital Mkts | Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Buy |
| Jun-05-19 | Upgrade | Standpoint Research | Hold → Buy |
| Apr-29-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Apr-15-19 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-10-19 | Reiterated | BofA/Merrill | Buy |
| Mar-13-19 | Initiated | Bernstein | Outperform |
| Feb-20-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-18-18 | Initiated | Barclays | Overweight |
| Nov-29-18 | Resumed | Goldman | Neutral |
| Nov-28-18 | Initiated | Evercore ISI | Outperform |
| Oct-26-18 | Resumed | Wolfe Research | Peer Perform |
| Jul-09-18 | Upgrade | Citigroup | Neutral → Buy |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-13-18 | Reiterated | Citigroup | Neutral |
View All
Cvs Health Corp Stock (CVS) Latest News
Putting pharmacy education within reach - CVS Health
CVS: Bernstein Raises Price Target for CVS Health to $87 | CVS S - GuruFocus
Bernstein raises CVS Health stock price target to $87 on Aetna growth potential - Investing.com
CVS Health Corporation $CVS is Camber Capital Management LP's 4th Largest Position - MarketBeat
CVS Health offering measles vaccine to South Carolina residents amid the state's current outbreak - Financial Times
Jim Cramer on CVS: "This Stock Has Become the Best Performer in the Healthcare Sector" - Finviz
Jim Cramer on CVS: “This Stock Has Become the Best Performer in the Healthcare Sector” - Insider Monkey
CVS Health (CVS) Receives Analyst Price Target Upgrade to $98 | - GuruFocus
CVS Health (CVS) Sees Analyst Rating Update from Piper Sandler | - GuruFocus
CVS Health Is Seeing Margin And App Momentum, Analyst Highlights - Benzinga
CVS Health Targets Steady Gains With A Revamped Game Plan - Finimize
CVS Health Stock (CVS) Opinions on 2025 Guidance Update - Quiver Quantitative
CVS Health (CVS) Analysts Maintain Overweight, Raise Price Targe - GuruFocus
UBS Maintains Buy Rating, Raises Price Target for CVS to $97 | C - GuruFocus
CVS Health Raises Its Long-Term Outlook And Stock Follows Suit - Finimize
CVS forecasts 2026 profit higher than Wall Street estimates - Providence Business News
CVS Health Corporation (CVS) Sees Higher Price Target Despite PBM Pressures - Insider Monkey
Mizuho Raises Price Target for CVS Health (CVS) to $95.00 | CVS Stock News - GuruFocus
CVS Health (NYSE:CVS) Price Target Raised to $98.00 at Truist Financial - MarketBeat
CVS Health (NYSE:CVS) Price Target Raised to $95.00 - MarketBeat
CVS Health (CVS) Receives Price Target Increase from Morgan Stan - GuruFocus
Cantor Fitzgerald reiterates Overweight rating on CVS Health stock - Investing.com
Piper Sandler raises CVS Health stock price target to $101 on growth outlook - Investing.com
CVS (CVS) Analyst Rating Update: Baird Raises Price Target to $9 - GuruFocus
CVS Health (NYSE:CVS) Given New $92.00 Price Target at Robert W. Baird - MarketBeat
Investment Management Corp of Ontario Has $5.74 Million Holdings in CVS Health Corporation $CVS - MarketBeat
Intact Investment Management Inc. Sells 20,100 Shares of CVS Health Corporation $CVS - MarketBeat
Morgan Stanley raises CVS Health stock price target to $93 on turnaround - Investing.com
RBC Capital reiterates Outperform rating on CVS Health stock with $93 target - Investing.com
Truist Securities raises CVS Health stock price target to $98 on upbeat outlook - Investing.com
Natixis Has $8.36 Million Stock Position in CVS Health Corporation $CVS - MarketBeat
CVS Health Corporation $CVS Shares Purchased by State Street Corp - MarketBeat
3 Reasons CVS is Risky and 1 Stock to Buy Instead - Finviz
CVS Health stock price target raised to $97 from $96 at UBS - Investing.com
BofA Securities reiterates Buy rating on CVS Health stock with $100 target - Investing.com
Daiwa Securities Group Inc. Purchases 37,509 Shares of CVS Health Corporation $CVS - MarketBeat
CVS Health stock price target raised to $95 by Mizuho on positive outlook - Investing.com
TD Cowen raises CVS Health stock price target to $105 on Medicare Advantage recovery - Investing.com
How Recent Shifts Are Rewriting the Story for CVS Health - Yahoo Finance
Ariel Investments LLC Purchases 144,541 Shares of CVS Health Corporation $CVS - MarketBeat
CVS Health Corporation (NYSE:CVS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
CVS raises profit forecast as turnaround plan takes effect - Honolulu Star-Advertiser
CVS forecasts 2026 profit above estimates as turnaround plan takes effect - Denver Gazette
CVS boosts profit outlook in sign of momentum as 2026 nears - The Boston Globe
CVS Health Hikes Its Outlook, and Says It Plans to Roll Out AI Platform - Investopedia
CVS Raises Profit Outlook in Sign of Momentum for 2026 - Transport Topics
Meet the 2.5% Yield Dividend Stock That Could Soar in 2026 - The Motley Fool
Is It Time to Bet on CVS Health? - StocksToTrade
CVS Health: Investor Day Targets Set Attractive Baseline For 2026 (CVS) - Seeking Alpha
CVS Forecasts 2026 Revenue Short of Wall Street Estimates - Bloomberg.com
Why CVS Health (CVS) Stock Is Up Today - Finviz
Cvs Health Corp Stock (CVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.32%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):